Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab (Q35225259)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Timothy F. Cloughesy

2

object named as

Timothy F Cloughesy

1 reference

Europe PubMed Central

7 August 2017

3

object named as

Albert Lai

1 reference

Europe PubMed Central

7 August 2017

Phioanh Nghiemphu

5

object named as

Phioanh L Nghiemphu

1 reference

Europe PubMed Central

7 August 2017

Benjamin M Ellingson

1

object named as

Benjamin M Ellingson

1 reference

Europe PubMed Central

7 August 2017

8

object named as

Whitney B Pope

1 reference

Europe PubMed Central

7 August 2017

4

object named as

Paul S Mischel

1 reference

Europe PubMed Central

7 August 2017

6

object named as

Shadi Lalezari

1 reference

Europe PubMed Central

7 August 2017

author name string

Kathleen M Schmainda

7

1 reference

Europe PubMed Central

7 August 2017

publication date

19 August 2011

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

13

1 reference

Europe PubMed Central

7 August 2017

10

1 reference

Europe PubMed Central

7 August 2017

1151-1161

1 reference

Europe PubMed Central

7 August 2017

Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Molecular mechanisms of developmental and tumor angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

13 July 2018

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Effect of bevacizumab on radiation necrosis of the brain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3177656

26 September 2018

Real-time 3D image registration for functional MRI

1 reference

https://pubmed.ncbi.nlm.nih.gov/21856685

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NEUONC/NOR079

1 reference

Europe PubMed Central

7 August 2017

release_2lzpn2ub6bd7rfs7xjlioy6tca

1 reference

https://api.fatcat.wiki/v0/release/2lzpn2ub6bd7rfs7xjlioy6tca

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35225259&oldid=1977362088"